Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–71 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: exenatide twice daily Clear all
Completed Phase 2 Interventional Results available

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

NCT00500370
View directory record Official record
Conditions
Obesity
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

NCT00353834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

NCT00546728
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Exenatide, Metformin
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 7, 2026, 7:31 AM EDT
Terminated Phase 4 Interventional Results available

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

NCT02793154
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide, Albiglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 2 Interventional Results available

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

NCT00886626
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Exenatide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

NCT00877890
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide as Monotherapy

NCT00381342
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Idaho Falls, Idaho • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 7, 2026, 7:31 AM EDT
Completed No phase listed Observational

Impact of Exenatide on Sleep Duration

NCT01416649
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00035984
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
100
States / cities
Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

NCT00111540
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Not applicable Interventional Results available

Impact of Exenatide on Sleep in Type 2 Diabetes

NCT01136798
View directory record Official record
Conditions
Type 2 Diabetes, Sleep Disordered Breathing
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

NCT00658021
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 2 Interventional

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 7, 2026, 7:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

NCT00099320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 75 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 7, 2026, 7:31 AM EDT